Natera (MEX:NTRA) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NTRA Natera Inc MEX:NTRA
60 GF Score
Price MXN3,905.00
GF Value MXN2,983.49
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Natera SpecialCharges?

Special Charges only applies to banks.

MEX:NTRA
60GF Score
Natera Inc MEX:NTRA
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Natera (MEX:NTRA) Overvalued in 2026?

Based on GuruFocus' analysis, Natera stock appears to be overvalued. The current stock price of MXN3,905.00 is trading 30.9% above its estimated GF Value™ of MXN2,983.49. GuruFocus considers Natera to be Significantly Overvalued.

Key valuation signals for MEX:NTRA:

  • SpecialCharges:
  • GF Value™: MXN2,983.49 vs. price of MXN3,905.00 (30.9% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natera Business Description

Other Exchanges NTRA:USA45E:Germany
Address 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
60GF Score

Get the complete analysis for MEX:NTRA

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,905.00
Price
MXN2,983.49
GF Value